Molecular Therapies in Hepatocellular Carcinoma: What Can We Target?

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health

(2015) William H. Chappell et al.   Oncotarget

Targeting the MAPK–RAS–RAF signaling pathway in cancer therapy

(2012) Libero Santarpia et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Combination therapy for hepatocellular carcinoma: Additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib

(2012) Anja Lachenmayer et al.   JOURNAL OF HEPATOLOGY

Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design

(2012) Marta Burrel et al.   JOURNAL OF HEPATOLOGY

New agents on the horizon in hepatocellular carcinoma

(2012) Andrew X. Zhu   Therapeutic Advances in Medical Oncology

Targeted Therapies for Hepatocellular Carcinoma

(2011) Augusto Villanueva et al.   GASTROENTEROLOGY

Obesity, inflammation, and liver cancer

(2011) Beicheng Sun et al.   JOURNAL OF HEPATOLOGY

PKI-587 and Sorafenib Targeting PI3K/AKT/mTOR and Ras/Raf/MAPK Pathways Synergistically Inhibit HCC Cell Proliferation

(2011) Roberto Gedaly et al.   JOURNAL OF SURGICAL RESEARCH

Hepatocellular Carcinoma

(2011) Hashem B. El-Serag   NEW ENGLAND JOURNAL OF MEDICINE

Notch signaling: Emerging molecular targets for cancer therapy

(2010) Ling Yin et al.   BIOCHEMICAL PHARMACOLOGY

Cell Signaling by Receptor Tyrosine Kinases

(2010) Mark A. Lemmon et al.   CELL

Loco-regional treatment of hepatocellular carcinoma

(2010) Riccardo Lencioni   HEPATOLOGY

Current status of molecularly targeted therapy for hepatocellular carcinoma: clinical practice

(2010) Masatoshi Kudo   International Journal of Clinical Oncology

Current Strategy for Staging and Treatment: The BCLC Update and Future Prospects

(2010) Alejandro Forner et al.   SEMINARS IN LIVER DISEASE

Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis

(2009) S J Schoenleber et al.   BRITISH JOURNAL OF CANCER

Pathogenesis of hepatocellular carcinoma and molecular therapies

(2009) Beatriz Mínguez et al.   CURRENT OPINION IN GASTROENTEROLOGY

Angiogenesis in liver disease

(2009) Mercedes Fernández et al.   JOURNAL OF HEPATOLOGY

Small-molecule modulators of the Sonic Hedgehog signaling pathway

(2009) Benjamin Z. Stanton et al.   Molecular BioSystems

Metabolic Factors and Risk of Hepatocellular Carcinoma by Chronic Hepatitis B/C Infection: A Follow-up Study in Taiwan

(2008) Chi–Ling Chen et al.   GASTROENTEROLOGY

Diagnosis and Treatment of Hepatocellular Carcinoma

(2008) Hashem B. El-Serag et al.   GASTROENTEROLOGY

Overexpression of VEGF is associated with positive p53 immunostaining in hepatocellular carcinoma (HCC) and adverse outcome of HCC patients

(2008) Po-Lin Tseng et al.   JOURNAL OF SURGICAL ONCOLOGY

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

(2008) Ann-Lii Cheng et al.   LANCET ONCOLOGY

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE